3rd Cell Therapy for Autoimmune Disease Summit

Power Targeted Therapeutic and Clinical Breakthroughs Across Different Autoimmune Cell Therapies with Proven Safety, Sustained Efficacy, and Greater Patient Access to Redefine Chronic Care of Autoimmune Diseases.

Ever since cell therapies demonstrated potential in lupus and beyond, focus has shifted from oncology to advancing the first approved autoimmune cell therapy to market.

The 3rd Cell Therapy for Autoimmune Disease Summit returns at a transformative moment for this field, as autoimmune therapies stand poised to lead the next frontier of cell therapy innovation. As the only forum spotlighting breakthroughs across CAR-T, Treg, NK and in vivo cell therapies, this is your opportunity to gain end-to-end insights to navigate the dynamic, high-velocity road to market.

Uncover first-hand experiences from industry titans including Cabaletta Bio, Kyverna Therapeutics, Umoja Biopharma, Cartesian Therapeutics, Century Therapeutics, Artiva Biotherapeutics and Novartis, to accelerate your therapeutic progression and remain ahead of your peers.

From target selection and IND preparation to clinical trial design, patient recruitment, and long-term data, this year's edition will empower you to translate clinical promise into real breakthroughs.

URLs:
Website: https://go.evvnt.com/3185607-0?pid=2874
Brochure: https://go.evvnt.com/3185607-3?pid=2874

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:
Conference Only- Drug Developer Pricing: USD 2899.00,
Conference + 1 Workshop- Drug Developer Pricing: USD 3598.00,
Conference + 2 Workshops - Drug Developer Pricing: USD 4197.00,
Conference Only- Academic Pricing: USD 2599.00,
Conference + 1 Workshop- Academic Provider Pricing: USD 3098.00,
Conference + 2 Workshops- Academic Provider Pricing: USD 3597.00,
Conference Only- Solution Pricing: USD 3699.00,
Conference + 1 Workshop- Solution Pricing: USD 4398.00,
Conference + 2 Workshops- Solution Pricing: USD 5097.00

Speakers: Fred Aslan, President and Chief Executive Officer, Artiva Biotherapeutics, Inc, Jennifer Bush, Chief Operating Officer, Artiva Biotherapeutics, Inc, Marko Radic, Ph.D. Associate Professor, The University of Tennessee Health Science Center, Samik Basu, Chief Scientific Officer, Cabaletta Bio, Susanne Diehl, Global Program Head Immunology, Novartis, Adil Doganay Duru, Director, Business Development, Glycostem Therapeutics, Christopher Jewell, Chief Scientific Officer, Cartesian Therapeutics, Christopher Tehlirian, Executive Medical Director, Legend Biotech, Clinton Weber, Vice President, CMC Strategy, Umoja Biopharma, Daniel Shelly, Chief Business Development Officer, PolTREG Immuthera, Ed Zhang, Co-Founder and Chief Executive Officer, Overland Pharmaceuticals, Gilles Besin, Chief Scientific Officer, Orbital Therapeutics, Jeff Liter, Chief Executive Officer, Luminary Therapeutics, Jenell Volkov, Senior Director - Translational Medicine, Cabaletta Bio, Jennifer Chow, Chief Executive Officer, iCell Gene Therapeutics, Jim Sesic, Senior Vice President, Regulatory Affairs, Atara Biotherapeutics Inc., Laurie Beitz MD, Executive Director Research, Umoja Biopharma, Luke Devey, Chief Medical Officer, Quell Therapeutics, Mark Bach, Chief Medical Officer, GentiBio, Melissa Fernandes, Medical Director, Rheumatology, Novartis AG, Naji Gehchan, Chief Medical and Development Officer, Kyverna Therapeutics, Inc., Nikhil Mutyal, Head, Search, Evaluation, Respiratory and Immunology, AstraZeneca, Patricia Beaston, Independent Consultant, Former FDA (2000-2024), Phung Gip, Senior Director and Head of Translational Medicine, Nkarta Inc, Shawn Rose, Chief Medical Officer and Head, Research and Development, Nkarta Therapeutics, Teresa Whalen, Chief Executive Officer, CytoAgents, Timmothy Taps, Executive Director and Head of Regulatory Affairs, Strategy and Operations, Century Therapeutics, Warner Biddle, Chief Executive Officer, Kyverna Therapeutics, Inc.